Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb Hepatocellular Carcinoma
Latest Information Update: 30 Jan 2024
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Bone metastases; Cancer metastases; Liver cancer
- Focus Therapeutic Use
- 21 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 21 Jan 2024 Planned primary completion date changed from 31 May 2023 to 30 Sep 2024.
- 04 Sep 2022 Planned End Date changed from 31 Jan 2023 to 31 Dec 2023.